

3-CONTAM Contaminants in the food chain 2012-2015							
Expert name	Declared interests	Complementary information	EFSA cat	EFSA	CEO	Red flag	Grey zone
BENFORD Diane CHAIR	1# Member of ILSI Europe Expert Group on Data Selection for BMD Modelling. This activity was an expert group aiming to advance risk assessment methodology. My participation was on behalf of the Food Standards Agency in support of its aim to use best scientific evidence, and was 100% funded by the Food Standards Agency. It did not involve advice, consultancy or services to ILSI Europe, and as far as is known has not been used by ILSI Europe. The output is a peer-reviewed journal and will be used by food safety organisations including EFSA. 09/2009 - 04/2012.	1# International Life Sciences Institute (ILSI) is an industry-funded organisation.	1# V	1# yes	1# yes	<b><u>According to EFSA rules, Diane Benford should not be allowed to chair the CONTAM panel. Her recent, past consultancies with ILSI (1 and 2#) are considered conflicts of interests.</u></b>	
	2# Member of ILSI Europe expert group on the Margin of Exposure approach to substances that are genotoxic and carcinogenic, in support of EFSA and WHO activities. This activity was an expert group aiming to advance risk assessment methodology. My participation was on behalf of the Food Standards Agency in support of its aim to use best scientific evidence, and was 100% funded by the Food Standards Agency. It did not involve advice, consultancy or services to ILSI Europe, and as far as is known has not been used by ILSI Europe. The output was a peer-reviewed journal and is used by FSOs including EFSA. 07/2006 - 01/2010.	2# International Life Sciences Institute (ILSI) is an industry-funded organisation.	2# V	2# yes	2# yes	A few omissions in Diane Benford's DoI were reported in a December 2012 report by Stéphane Horel:  a-Diane Benford also chaired the ILSI Europe expert group on the "Application of the Margin of Exposure (MOE)..." (2#) at an <a href="#">ILSI workshop</a> (1-3/10/2008, Rhodes, Greece) and co-authored the <a href="#">ILSI publication</a> : Benford D, Bolger PM, Carthew P, Coulet M, DiNovi M, Leblanc JC, Renwick AG, Setzer W, Schlatter J, Smith B, Slob W, Williams G, Wildemann T. <i>Application of the Margin of Exposure (MOE) approach to substances in food that are genotoxic and carcinogenic. Food Chem Toxicol.</i> 2010 Jan;48 Suppl 1:S2-24. Review.	
	3# Honorary member of the European Society of Toxicology In Vitro (ESTIV). 07/1996 – now.	3# The European Society of Toxicology In Vitro (ESTIV) has 5 corporate members: <a href="#">Roche</a> , a pharmaceutical company ("golden sponsor"); <a href="#">Epithelix</a> , an in-vitro tests company; <a href="#">Novozymes</a> , a biotech company; <a href="#">Vito</a> a R&D technology company; <a href="#">Thor</a> , a personal care products company.	3# VIII	3# CbC	3# no	b-She was a speaker on behalf of ILSI at <a href="#">EUROTOX 2008 congress</a> . "Overview of the work of the expert group on MoE and report back on the workshop".	
	4# Registered toxicologist at the Association of European Toxicologists and European Societies of Toxicology (EUROTOX). 01/1990 - now.	4# The Association of European Toxicologists and European Societies of Toxicology (EUROTOX) has 5 corporate members: <a href="#">AstraZeneca</a> , <a href="#">Servier</a> (pharmaceutical companies); <a href="#">Solvay</a> (chemical company); <a href="#">Research Toxicology Centre</a> , <a href="#">MPI research</a> (Contract Research Organisations - CROs).	4# VIII	4# CbC	4# no	c-She is member of the editorial board of " <a href="#">Regulatory Toxicology and Pharmacology</a> ", whose editor <a href="#">Gio Gori</a> has worked many years for the tobacco industry. The journal's owner, the International Society of Regulatory Toxicology & Pharmacology (ISRTP) is an association dominated by industry scientists and	
	5# British Toxicology Society (BTS). Fellow of the Society. Education and	5# The British Toxicology Society (BTS) is " <a href="#">grateful for donations from the following</a>	5# VIII	5# CbC	5# yes		

	<p>training in Toxicology. Director of the Society April 2004-March 2008. 01/1980 – now.</p> <p>6# ECETOC-WHO Workshop on Mode of Action, funded by Food Standards Agency. 21-22.02.2013.</p>	<p><u>companies</u>": <a href="#">GlaxoSmithKline</a>, <a href="#">AstraZeneca</a>, <a href="#">Roche</a>, pharmaceutical companies, <a href="#">Johnson Matthey</a>, chemical company ("Diamond level"); <a href="#">Unilever</a>, a food company ("Platinum level") <a href="#">Syngenta</a>, a pesticides and GMO company ("Gold level").</p> <p>6# The European Centre for Ecotoxicology and Toxicology of Chemicals (<a href="#">ECETOC</a>) is a industry organisation funded by <a href="#">chemical, pesticide and oil companies</a>, including <a href="#">BASF</a> and <a href="#">Bayer</a>. <a href="#">WHO</a> is the World health organisation.</p>	6# IX	6# CbC	6# yes	<p>consultants of regulatory firms who work for the industry. ISRTP has been announcing to disclose its sponsors "soon" <a href="#">since 2009</a>. <a href="#">In 2007</a>, ISTRP had, among its 6 sponsors: <a href="#">Coca-Cola</a>, a drink company; <a href="#">Monsanto</a>, a GMO company; and <a href="#">The Weinberg Group</a>, a product defence company <a href="#">working for the tobacco, the chemical (bisphenol-A and PFOA) and the pharmaceutical (Vioxx) industries</a>. <a href="#">In 2006</a>, among many others, <a href="#">RJ Reynolds</a>, a tobacco Company, was also listed as a sponsor. (Source: <a href="#">Stéphane Horel</a>, <a href="#">Conflicts of interests at EFSA – season 10, 11.12.2012</a>)</p> <p>Had they been recorded in her DOI (sector V "Consultancy"), her collaborations a and b with ILSI would have been considered conflicts of interests by EFSA.</p> <p><b><u>Diane Benford has omitted these interests and has not updated her DOI since they were made public in December 2012. According to EFSA rules, a breach of trust procedure could be started.</u></b></p>
CECCATELLI Sandra COTTRILL Bruce	<p>1# I was employed by ADAS UK Ltd until April 2012. ADAS is a privately owned company providing environmental services and policy advice to the agricultural industries, regional and authorities and the UK Government and its Agencies. It includes risk management, but not related to food or feed. While employed with the Company I undertook reviews of scientific literature and produced guidance documents on livestock nutrition, feeds and feeding systems. I was not involved in any research (either public or commercially funded), consultancy or risk management relating to contaminants in food or feed on behalf of ADAS in the last 5 years. I retired from ADAS in April</p>	<p>1# <a href="#">ADAS</a> is a private consultancy firm. In 2008, it was commissioned by the <a href="#">European Crop Protection Association</a> (ECPA – the European organisation for pesticides and GMOs producers) to write a <a href="#">report</a> on the potential impacts of proposals by the European Commission and European Parliament about "cut-off criteria" for pesticides that are carcinogenic, mutagenic, reprotoxic (CMR), persistent bioaccumulative toxic (PBT), and endocrine-disruptors.</p>	1# IV	1# CbC	1# yes	

	2012, and have no further involvement with the Company. 01/2000 - 04/2012.						
DINOVI Michael	<p>1# I have been a non-voting member of the ILSI Europe Expert Workgroup on GuiDEA - Guidance for Dietary Exposure Assessment, as well as a member of its Advisory Group. This project aims to prepare a publicly-accessible tool for designing and carrying out dietary exposure assessments for substances found in, or added to, food. As a working member of the group, I have prepared and presented information concerning the preparation of dietary exposure assessments and offered opinions on the use of a web-based tool for dissemination of the information. The tool will be offered under the aegis of ILSI at no cost to users. I have resigned these positions effective Apr. 27, 2012. In order to have participated in this activity without violating US FDA ethics rules*, I have never accepted any payments from ILSI - neither cash, in-kind, meeting, or travel expenses. I did not prepare any dietary exposure assessments for acrylamide for this activity. 01/2009 - 04/2012.</p> <p>[*Michael DINOVI is employed by the US Food and Drug Administration (FDA)]</p>	1# International Life Sciences Institute (ILSI) is an industry-funded organisation.	1# V	1# no	1# yes		
DOGLIOTTI Eugenia	<p>1# Research funding from the Italian Association on Cancer Research (Associazione Italiana per la Ricerca sul Cancro, AIRC). AIRC is a non-profit private organization. The funding from this organization does not exceed 25% of the budget of my laboratory in the last financial year. 10/2008 - now.</p> <p>2# European Environmental Mutagen Society (EEMS). Member, president (09/2007-2009). 01/1991 - now.</p> <p>3# Italian Society of Environmental Mutagenesis (SIMA). Member, president (2004-2007). 01/1991 - now.</p>	<p>1# The Italian Association on Cancer Research (Associazione Italiana per la Ricerca sul Cancro - AIRC) is a research funding organisation.</p> <p>2# The European Environmental Mutagen Society (EEMS) is sponsored by <a href="#">Unilever</a>, a food company; <a href="#">Harlan</a> a biotech company; <a href="#">Givaudan</a>, a flavour and fragrance company; <a href="#">Huntingdon Life Sciences</a>, a contract research organisation (CRO); and <a href="#">Glaxo SmithKline</a>, a pharmaceutical company.</p> <p>3# No information could be found on the Italian Society of Environmental Mutagenesis (SIMA)'s funding.</p>	1# VI	1# no	1# no		
			2# VIII	2# CbC	2# yes		
			3# VIII	3# CbC	3# ?		
EDLER Lutz	1# Board Member of CESAR-EWIV, CESAR (Central European Society for Anticancer Drug Research). Pharmaceutical drug development through clinical trials in cooperation with	1# The <a href="#">advisory board</a> of (Central European Society for Anticancer Drug Research - CESAR-EWIV / CESAR) includes 6 pharmaceutical companies : <a href="#">4SC</a> , <a href="#">Bayer Vital</a> , <a href="#">Boehringer Ingelheim</a> , <a href="#">Daiichi Sankyo</a> , <a href="#">Lilly</a>	1# II	1# no	1# yes		

	<p>pharmaceutical industry. Function: Responsible statistician of the Section for Biometry of CESAR-EWIV. 01/2002 - 07/2011.</p> <p>2# Treasurer of the "Verein" Central European Society for Anticancer Drug Research (CESAR)-Deutschland CESAR-Deutschland. 01/2001 - 12/2010.</p> <p>3# 4SC. Member of the Data Safety Monitoring Board (DSMB) for the clinical Phase I/II Study, called SHORE Study. 12/2010 - now.</p> <p>4# 4SC. Member of the Data Safety Monitoring Board (DSMB) for the clinical Phase I Study, called AEGIS Study. 03/2010 - 12/2011.</p> <p>5# Covance Clinical Research Unit Ltd. Member of the Safety Monitoring Board of POL6326 Clinical Trial in Multiple Myeloma Patients. 04/2009 - 06/2011.</p> <p>6# Biostatistician at Deutsches Krebsforschungszentrum (German Cancer Research Center – DKFZ-) Heidelberg, Germany. Research Funding was exclusively handled by the administration of the DKFZ. The private sector includes the pharmaceutical companies Eli Lilly Deutschland, Homburg, Oncoscience Hamburg-Wedel, CESAR-EWIV, Vienna. 07/1991 - 02/2010.</p> <p>7# Leader of workpackage 6 in EU FP7* project BASELINE - Selection and improving of fit-for-purpose sampling procedures for specific foods and risks. Research for the Deutsches Krebsforschungszentrum (German Cancer Research Center – DKFZ). 03/2011 - now.</p> <p>8# ILSI Europe. Chair and member of the Expert Group on data selection for Benchmark Dose (BMD) modelling. Publication. 09/2009 - 04/2012.</p> <p>9# ILSI Europe. Member of the Expert Committee on Eliciting Dose of Allergens in Food. 07/2003 - 12/2008.</p>	<p><a href="#">Deutschland, Merck.</a></p> <p>2# The Central European Society for Anticancer Drug Research (CESAR)-Deutschland is part of <a href="#">CESAR-EWIV</a> (see above 1#). Its <a href="#">members</a> include private actors.</p> <p>3# <a href="#">4SC</a> is a pharmaceutical company.</p> <p>4# <a href="#">4SC</a> is a pharmaceutical company.</p> <p>5# <a href="#">Covance Clinical Research Unit Ltd.</a> is a private Contract Research Organisation (CRO) for drug development.</p> <p>6# The German Cancer Research Center (Deutsches Krebsforschungszentrum - <a href="#">DKFZ</a>) is a public research institute. <a href="#">Eli Lilly Deutschland</a> and <a href="#">Oncoscience</a> are pharmaceutical companies. The <a href="#">advisory board</a> of (Central European Society for Anticancer Drug Research - CESAR-EWIV / CESAR) includes 6 pharmaceutical companies : <a href="#">4SC</a>, <a href="#">Bayer Vital</a>, <a href="#">Boehringer Ingelheim</a>, <a href="#">Daiichi Sankyo</a>, <a href="#">Lilly Deutschland</a>, <a href="#">Merck</a>.</p> <p>7# <a href="#">BASELINE consortium</a> includes private partners such as <a href="#">Nordlaks</a>, a food company or <a href="#">Tecnoalimenti S.C.P.A.</a>, a joint private-public non-profit research consortium focussed on agrifood research, and composed of 28 agrifood sector industries. One of the 5 external <a href="#">advisory board members</a> is an employee of the food company <a href="#">Barilla</a>.</p> <p>8# International Life Sciences Institute (<a href="#">ILSI</a>) is an industry-funded organisation.</p> <p>9# International Life Sciences Institute (<a href="#">ILSI</a>) is an industry-funded organisation.</p>	<p>2# II</p> <p>3# II</p> <p>4# II</p> <p>5# II</p> <p>6# IV</p> <p>7# V</p> <p>8# V</p> <p>9# V</p>	<p>2# no</p> <p>3# CbC</p> <p>4# no</p> <p>5# no</p> <p>6# no</p> <p>7# no</p> <p>8# no</p> <p>9# no</p>	<p>2# yes</p> <p>3# yes</p> <p>4# yes</p> <p>5# yes</p> <p>6# yes</p> <p>7# ?</p> <p>8# yes</p> <p>9# yes</p>		<p>6# Public research institute receiving funds from the private sector.</p> <p>7# EU-funded project with private beneficiaries.</p>
--	---	--	--	--	---	--	--

	10# Member of the Executive Board of the International Society of Clinical Biostatistics (ISCB) and Member of the Subcommittees on Congress Organization (Scientific Secretary) and on Regulatory Affairs (SIRA). 01/2009 - now.	10# The International Society of Clinical Biostatistics (ISCB)'s 2013 annual conference is sponsored by pharmaceutical companies including <a href="#">Merck Serono</a> , <a href="#">Novartis</a> and <a href="#">Pfizer</a> .	10# VIII	10# CbC	10# yes		
FARMER Peter	<p>1# Share owner Santander, bank and investment company, not food related 11/2004 - now.</p> <p>2# Share owner Foreign and Colonial. Investment company, not food related. 08/1992 - now.</p> <p>3# Share owner Friends Provident Investment company. Not food related. 07/2001 - 11/2009.</p> <p>4# Share owner Bradford and Bingley plc. Bank. Not food related. 12/2000 - 09/2008.</p> <p>5# Member of Research Committee of the Health Effects Institute (HEI), which provides research funding on air pollution and motor vehicle emissions. Provided advice on research grant applications. 05/2000 - 06/2008.</p> <p>6# ILSI Health and Environmental Sciences Institute (HESI) (non-profit organisation). Member of the Biomonitoring Technical Committee (non remunerated). Provided advice on this subject. Publications may be prepared by ILSI/HESI committees. 12/2004 - 09/2012.</p> <p>7# ILSI Health and Environmental Sciences Institute (HESI) (non-profit organisation). Member of the Biological Significance of DNA Adducts Committee, (non-remunerated). Provided advice on this subject and contributions to publications. 12/2004 - 04/2012.</p> <p>8# Several European Commission research grants on environmental carcinogenesis, biomarkers of carcinogenesis in mothers and newborns, polycyclic aromatic hydrocarbons, nanoparticles. The research (co-)funding I received from the private sector in the latest full budget</p>	<p>1# <a href="#">Santander</a> is a bank and investment company.</p> <p>2# <a href="#">Foreign and Colonial</a> is an investment company.</p> <p>3# <a href="#">Friends Provident</a> is an investment company.</p> <p>4# <a href="#">Bradford and Bingley</a> is a bank.</p> <p>5# <a href="#">Half</a> of the Health Effects Institute (HEI)'s core funds are provided by the <a href="#">motor vehicle industry</a>. Other sponsors include oil companies.</p> <p>6# The Health and Environmental Science Institute (HESI) is an ILSI structure. International Life Sciences Institute (ILSI) is an industry-funded organisation.</p> <p>7# The Health and Environmental Science Institute (HESI) is an ILSI structure. International Life Sciences Institute (ILSI) is an industry-funded organisation.</p> <p>8# Insufficient information.</p>	1# I	1# CbC	1# ?	1# Insufficient declared information to assess the interest.	
			2# I	2# CbC	2# ?	2# Insufficient declared information to assess the interest.	
			3# I	3# CbC	3# ?	3# Insufficient declared information to assess the interest.	
			4# I	4# CbC	4# ?	4# Insufficient declared information to assess the interest.	
			5# III	5# no	5# yes		
			6# III	6# no	6# yes		
			7# III	7# no	7# yes		
			8# VI	8# no	8# ?	8# Insufficient declared information to assess the interest.	

	<p>year, and for the areas covered by the Panels, does not exceed 25% of the total annual research budget that is managed by me. 01/2004 - now.</p> <p>9# British Association for Cancer Research (BACR). Member 01/1980 - 09/2012.</p> <p>10# American Association for Cancer Research (AACR). Member. 01/1995 - 12/2010.</p>	<p>9# The British Association for Cancer Research (<b>BACR</b>) is <b>sponsored</b> by pharmaceutical companies <b>AstraZeneca</b>, <b>Abcam</b>, <b>Bayer Healthcare</b> and <b>Roche Applied Science</b>. It is not clear whether BACR is a scientific society or an association.</p> <p>10# The American Association for Cancer Research (<b>AACR</b>)'s corporate <b>sustaining members</b> consists in 21 pharmaceutical companies including <b>Eisai</b>, <b>Janssen</b> or <b>Servier</b>. AACR's <b>governance boards</b> include employees of the pharmaceutical industry. AACR's annual meetings and programmes are <b>sponsored</b> by numerous pharmaceutical companies including <b>Amgen</b> or <b>Merck</b>.</p>	9# VIII	9# CbC	9# ?		
FURST Peter <b>VICE-CHAIR</b>	<p>1# Gesellschaft Deutscher Chemiker (Association of German Chemists - GDCh). Member. 01/1976 - now.</p> <p>2# Association of German Food Chemists inside Gesellschaft Deutscher Chemiker (Association of German Chemists - GDCh). Member. 01/1976 - now.</p>	<p>1# The two vice-presidents of the German Society of Chemists (Gesellschaft Deutscher Chemiker - <b>GDCh</b>)'s <b>board</b> and the treasurer are employees of the chemical and pharmaceutical industries. Although the website does not mention it, GDCh's vice-president <b>Michael Dröscher</b> works for <b>Chemie.NRW</b>, which is part of the Verband der Chemischen Industrie (VCI), the German organisation of the chemical industry.</p> <p>2# The two vice-presidents of the German Society of Chemists (Gesellschaft Deutscher Chemiker - <b>GDCh</b>)'s <b>board</b> and the treasurer are employees of the chemical and pharmaceutical industries. Although GDCh's website does not mention it, vice-president <b>Michael Dröscher</b> works for <b>Chemie.NRW</b>, which is part of the Verband der Chemischen Industrie (VCI), the German organisation of the chemical industry.</p>	1# VIII	1# CbC	1# yes		
HOOGENBOOM Laurentius (Ron)	<p>1# Programme leader Food Contaminants and project leader in research projects at RIKILT, a privatized research institute and part of Wageningen University and Research. Most work is performed for the Dutch authorities (Ministry of Economics, Agriculture and Innovation). Work for companies is only performed if accepted by the authorities, meaning that there is no conflict of interest. In case of analysis for companies, non-compliant results are</p>	<p>1# <b>RIKILT</b> is a privatized research institute and part of <b>Wageningen University and Research</b>. RIKILT's <b>clients</b> include private companies and EFSA.</p>	1# IV	1# no	1# ?	1# Insufficient declared information to assess the interest.	1# Public agency providing paid services to the private sector.

	<p>reported to the authorities. 09/1985 - now.</p> <p>2# Laboratory audit to 3 labs involved in dioxin analysis in Chile for APA (Association of Poultry Producers in Chile) and Asprocer (Association of Pork Producers in Chile). 03/2012 - 04/2012.</p> <p>3# Report on whether there is a potential relationship between a dioxin incident and elevated dioxin levels observed in pigs. Confidential Client. 01/2012 - 02/2012.</p> <p>4# EU FP7* project QSAFFE - Quality and Safety of Feeds and Foods for Europe. Leader of Workpackage WP4. 03/2011 - now.</p> <p>5# Screening of food and feed samples for dioxins and dl-PCBs for companies, under special agreement about reporting of positive results to authorities. All work is applied on behalf of RIKILT and the money goes directly to RIKILT. The research (co-)funding I received from the private sector in the latest full budget year, and for the areas covered by the Panels, does not exceed 25% of the total annual research budget that is managed by me. 01/2006 – now.</p>	<p>2# The Association of Poultry Producers in Chile (Asociación de Productores Avícolas de Chile - <a href="#">APA</a>) and the Association of Pork Producers in Chile (Asociación Gremial de Productores de Cerdos de Chile - <a href="#">Asprocer</a>) are trade associations.</p> <p>3# Consultancy activity for an unknown private company.</p> <p>4# <a href="#">QSAFFE consortium</a> includes private partners. <a href="#">Provimi Holding BV</a> – a subsidiary of <a href="#">Cargill</a> – and <a href="#">John Thompson and Sons Ltd</a> are animal feed companies.</p> <p>5# Insufficient information on the companies.</p>	2# V	2# no	2# yes		
			3# V	3# no	3# ?	3# Insufficient declared information to assess the interest.	
			4# VI	4# no	4# yes		4# EU-funded project with private beneficiaries.
			5# VI	5# no	5# ?	5# Insufficient declared information to assess the interest.	
KNUTSEN Helle Katrine	1# Partner in the EU-funded FP7* project ArcRisk - Arctic Health Risks: Impacts on health in the Arctic and Europe owing to climate-induced changes in contaminant cycling (226534). 06/2009 - now.	1# <a href="#">ArcRisk consortium</a> includes public research institutes and universities and one scientific consulting firm, whose clients are only from the public sector.	1# VI	1# no	1# no		
LUNDEBYE HALDORSEN Anne Katrine	1# EU-funded FP6** project "AquaMax" - Sustainable aquafeeds to maximise the health benefits of farmed fish for consumers. 03/2006 - 10/2010.	1# <a href="#">AquaMax consortium</a> included private partners of the farmed fish sector such as the Federation of European aquaculture producers ( <a href="#">FEAP</a> ).	1# VI	1# no	1# yes		1# EU-funded project with private beneficiaries.
	2# Research on dietary toxicity of endosulfan in salmon for Fisheries and aquaculture industry fund and the Norwegian Seafood Federation. 07/2009 - 03/2010.	2# The <a href="#">Fisheries and aquaculture industry fund</a> is related to the Norwegian Ministry of Fisheries. The <a href="#">Norwegian Seafood Federation</a> is a trade association.	2# VI	2# no	2# yes		
	3# Society of Environmental Toxicology and Chemistry (SETAC) Europe. Member. Council member (2005 – 2008). 01/1997 - 01/2012.	3# SETAC Europe is <a href="#">sponsored</a> by several private companies and organisations including <a href="#">EuroChlor</a> , the European organisation for the chlorine industry, or <a href="#">CEFIC</a> , the European organisation for the chemical industry. SETAC Global is <a href="#">sponsored</a> by several private companies, including <a href="#">ExxonMobil</a> , an oil	3# VIII	3# CbC	3# yes		

		company, or <a href="#">3M</a> , a chemical company. SETAC global is affiliated with ILSI's Health and Environmental Sciences Institute ( <a href="#">HESI</a> ). International Life Sciences Institute ( <a href="#">ILSI</a> ) is an industry-funded organisation.					
METZLER Manfred							
NEBBIA Carlo Stefano	<p>1# Grant for a study report awarded by Conad (Conad is a national retailer consortium) to the Department of Animal Pathology and managed by myself for a research project. "The research (co)funding I received from the private sector in the latest full budget year, and for the areas covered by the Panels, does not exceed 25% of the total annual research budget managed by myself". 01/2009 - now.</p> <p>2# Research and study report funded by Italian Ministry of Health, Italian Ministry of Research and University, Regione Piemonte, CONAD. 01/2002 - 12/2009.</p> <p>3# European Association for Veterinary Pharmacology and Toxicology (EAVPT). Member. 01/2002 - now.</p> <p>4# European College for Veterinary Pharmacology and Toxicology (ECVPT). Member. 01/2002 - now.</p>	<p>1# <a href="#">Conad</a> is a retailer private consortium.</p> <p>2# <a href="#">Conad</a> is a retailer private consortium.</p> <p>3# The European Association for Veterinary Pharmacology and Toxicology (EAVPT)'s 2102 annual international congress was <a href="#">sponsored</a> by several private companies, including pharmaceutical companies <a href="#">Bayer</a> ("Gold sponsor") or <a href="#">Pfizer</a> animal health (now <a href="#">Zoetis</a>).</p> <p>4# No information about the European College for Veterinary Pharmacology and Toxicology (<a href="#">ECVPT</a>)'s fundings could be found. ECVPT is <a href="#">affiliated with EAVPT</a>, whose congresses are sponsored by several private companies (see above 3#).</p>	<p>1# VI</p> <p>2# VI</p> <p>3# VIII</p> <p>4# VIII</p>	<p>1# no</p> <p>2# no</p> <p>3# CbC</p> <p>4# CbC</p>	<p>1# yes</p> <p>2# yes</p> <p>3# no</p> <p>4# no</p>		
O'KEEFFE Michael	<p>1# Teagasc - Agricultural and Food Development Authority Research in food safety (chemical contaminants); veterinary drug residue testing as part of the Irish national residue monitoring plan under EC regulations; veterinary drug (anticoccidials, avermectins, nitrofurans, antimicrobials) and mycotoxin (aflatoxin) residue testing for meat, fish, dairy and veterinary drug manufacturing industries. Since April 2008, retired from employment with Teagasc. 01/1973 -03/2008.</p> <p>2# EU-funded FP6** project BioCop - New Technologies to Screen Multiple Chemical Contaminants in Foods. The research (co-)funding I received from the private sector in the latest full budget</p>	<p>1# <a href="#">Teagasc</a> is the Irish Agricultural and Food Development Authority (national public agency).</p> <p>2# BioCop consortium included <a href="#">13 private partners</a>, among which Nestec, a research centre owned by <a href="#">Nestlé</a>, a food company.</p>	<p>1# IV</p> <p>2# VI</p>	<p>1# no</p> <p>2# no</p>	<p>1# ?</p> <p>2# yes</p>	<p>1# Insufficient declared information to assess the interest.</p>	<p>1# Public agency providing paid services to the private sector.</p> <p>2# EU-funded project with private beneficiaries.</p>



	year, and for the areas covered by the Panel, did not exceed 25% of the total annual research budget that was managed by me. 01/2006 - 12/2009.						
RIETJENS Ivonne	<p>1# Member of the supervisory board of Royal Wessanen, a company in the European organic food market. The Supervisory Board mainly discusses finances communication. 04/2012 - now.</p> <p>2# Member of the Board of Trustees of the Health and Environmental Sciences Institute (HESI - USA). HESI is recognized by the United States Government as a publicly supported organization independently chartered from ILSI. The Board of Trustees of HESI mainly discusses communication issues, finances and programme strategy. From December 2010 onwards I resigned from this board. 01/2008 - 12/2010.</p> <p>3# Chair of the scientific advisory board of Brabant Life Sciences Seed Fund. This is a scientific advisory board giving advice on the scientific content and soundness of proposals. This scientific evaluation is used by the board of the Fund to take the scientific soundness into account in a selection of the projects proposed to the Fund. Brabant Life Sciences Seed Fund is a startup company incubator. I do not receive any remuneration for this activity and it is not a consultancy. 01/2011 - now.</p> <p>4# FEMA (FDA related) (Expert panel of the FLavour and Extract Manufacturer Association) (private and public). Safety assessment of flavours for the GRAS (Generally Recognised As Safe) notification by the FDA (Food and Drug Administration) in the USA. This advisory board gives a scientific opinion on safety of the proposed use of flavours for the FDA GRAS notifications in the USA. The advisory board has no vote and no veto but formulates opinions based on common agreement. I am a member of this advisory board. 02/2006 - now.</p> <p>5# Member of the scientific advisory board of NanoTox BV. Advise on development of new testing methods for nanomaterials. This task was started but</p>	<p>1# <a href="#">Royal Wessanen</a> is a food company. According to <a href="#">Bloomberg Businessweek</a>, Mrs Rietjens' total evaluated compensation is around 37.000\$ (28.380€).</p> <p>2# The Health and Environmental Science Institute (<a href="#">HESI</a>) is an ILSI structure. International Life Sciences Institute (<a href="#">ILSI</a>) is an industry-funded organisation.</p> <p>3# <a href="#">Brabant Life Sciences Seed Fund</a> is a venture capital fund specializing in seed and start up investments. According to <a href="#">Bloomberg Businessweek</a>, Mrs Rietjens is also a board member of this company.</p> <p>4# The Flavour and Extract Manufacturer Association (<a href="#">FEMA</a>) is the US trade association of the flavor industry. FEMA is a founding member of the International Organization of the Flavor Industry (<a href="#">IOFI</a>), the international association of the flavor industry, headquartered in Switzerland.</p> <p>5# <a href="#">NanoTox BV</a>. is a nanotechnology toxicological testing company. According to Bloomberg Businessweek, Mrs Rietjens is also a <a href="#">board member</a> of nanoTox.</p>	<p>1# II</p> <p>2# III</p> <p>3# III</p> <p>4# III</p> <p>5# III</p>	<p>1# CbC</p> <p>2# no</p> <p>3# CbC</p> <p>4# no</p> <p>5# no</p>	<p>1# yes</p> <p>2# yes</p> <p>3# yes</p> <p>4# yes</p> <p>5# yes</p>	<p>In June 2011, a CEO report commented on Ivonne Rietjens' situation in detail. (Source: <a href="#">Exposed: conflicts of interest among EFSA's experts on food additives Corporate Europe Observatory, 15 June 2011</a>)</p> <p>Ivonne Rietjens almost systematically declares that "The topic does not fall under the remit of the CONTAM Panel. In case topics on the agenda of the CONTAM Panel would relate to this activity I would declare an interest in the [specific] DOI." The June 2011 CEO report showed that it is not always true.</p> <p>In her 2013 DOI, Ivonne Rietjens gives misleading information.</p> <p>-She writes that "HESI is recognized by the United States Government as a publicly supported organization independently chartered from ILSI" (2#). In fact, the Health and Environmental Science Institute (<a href="#">HESI</a>) as well as ILSI are US federal tax-exempt nonprofit organizations (or "nonprofits"). This status is used by most US lobbying organisations and does not mean that HESI benefits from any official recognition from the US federal authorities.</p> <p>-She writes FEMA is "private and public" and that FEMA's activities are "FDA-related" (4#). Both mentions are untrue. FEMA is a business association whose president-elect is Arthur Schick from <a href="#">PepsiCo</a>. "FDA-related" might lead to think FEMA is affiliated with the US FDA. This is not</p>	

	<p>never effectuated. I was never involved in any scientific advice or meeting on issues for which an advice was asked or prepared. I had no role in decision making, no vote and no veto. 01/2007 - 01/2008.</p> <p>6# Consultancy for Unimills BV. Expert judgment on the safety assessment of 3-MCPD giving advise on using the BMD (Benchmark Dose Method) to derive a point of departure that could be used for revising the TDI (Tolerable Daily Intake). 06/2010 - 12/2010.</p> <p>7# Research funding from BASF. In vitro-in silico physiologically based models for describing placental transfer and its influence on developmental toxicity. As model compounds a series of azoles will be investigated. The project will be supervised by a co-worker, not by me. I will be the promotor of the PhD student and may be involved as a co-author in some of the publications. 01/2012 - now.</p> <p>8# International Organization of Flavor Industries (IOFI). Research funding on matrix effect in risk assessment of alkenylbenzenes. 01/2010 - now.</p> <p>9# Nestle Research Centre PhD projects on bioavailability of flavonoids and on physiologically based kinetic (PBK) modelling of bioactivation and detoxification and DNA adduct formation of alkenylbenzenes. 01/2005 - now.</p> <p>10# TNO (public and private). PhD project on physiologically based kinetic (PBK) modelling of cholesterol. 01/2002 - 12/2011.</p> <p>11# Polak Spices. Research on species differences, genetic polymorphisms and matrix effects in bioactivation of coumarin. 01/2007 - 01/2008.</p>	<p>6# <a href="#">Unimills</a> is a food company.</p> <p>7# <a href="#">BASF</a> is a chemical company.</p> <p>8# The <a href="#">International Organization of Flavor Industries</a> (IOFI) is the international trade association of flavor companies.</p> <p>9# <a href="#">Nestlé</a> is a food company.</p> <p>10# <a href="#">TNO</a> is a private research organisation with clients in the private and the public sectors.</p> <p>11# <a href="#">Polak spices</a> is a food ingredients company.</p>	6# V	6# no	6# yes	<p>the case. FEMA's expert panel reviews the safety of flavouring chemicals in order to submit dossiers to the FDA.</p> <p>In its <a href="#">29.06.2012 report to the European Parliament on the implementation of its independence policy 2007-2012</a>, EFSA officially responded on this case: "Ivonne Rietjens was a member of the FEMA expert panel and this interest was clearly declared in her annual declaration of interests. In this role, Rietjens did not have any direct relationship with members of FEMA or with companies submitting dossiers for the GRAS (generally regarded as safe) evaluation of substances. As advantage was evaluated by the FEMA expert panel under its conditions of intended use as flavouring substance only and not as a food additive, this interest was outside the remit of the ANS Panel and more generally of all EFSA's activities in which Rietjens participated. According to EFSA's 2007 Policy, such interests did not have to be declared."</p>	
SCHRENK Dieter <b>VICE-CHAIR</b>	<p>1# UE funded FP7* project SYSTEQ - The development, validation and implementation of human systemic Toxic Equivalencies (TEQs) as biomarkers for dioxin-like compounds. 03/2010 - now.</p> <p>2# Private. The research (co-)funding I</p>	<p>1# <a href="#">SYSTEQ consortium</a> consists of public research institutes and universities. <a href="#">Additional fundings</a> are provided by <a href="#">DOW Chemical Company</a> for purchase of compounds and <a href="#">General Electric Company</a> for purchase of human primary hepatocytes.</p> <p>2# Research funding from unknown private</p>	1# VI	1# no	1# no		1# EU-funded project with private beneficiaries.
	2# Private. The research (co-)funding I	2# Research funding from unknown private	2# VI	2# no	2# ?	2# Insufficient declared	

	<p>received from the private sector in the latest full budget year, and for the areas covered by the Panels, does not exceed 25 % of the total annual research budget that is managed by me. 01/2011 - 01/2012.</p> <p>3# EUROTOX. Chair of the Carcinogenesis Speciality Section. 9/2011 - now.</p> <p>4# Arzneimittelkommission der Deutschen Apotheker (AKM), the Drug Commission of the German Pharmacists, a non profit expert team dealing with all aspects of drug safety. Member. 01/2008 - now.</p> <p>5# Gesellschaft Deutscher Chemiker (Association of German Chemists - GDCh) a non-profit professional society. Member. 05/1996 - now.</p> <p>6# Deutsche Gesellschaft für experimentelle und klinische Pharmakologie und Toxikologie (DGPT), the German Society of Pharmacology and Toxicology. Member. 03/1987 - now.</p> <p>7# EUROTOX. Member of the Executive Committee. 02/2006 - 02/2009.</p>	<p>company/ies.</p> <p>3# The Association of European Toxicologists and European Societies of Toxicology (<a href="#">EUROTOX</a>) has 5 corporate members: <a href="#">AstraZeneca</a>, <a href="#">Servier</a> (pharmaceutical companies); <a href="#">Solvay</a> (chemical company); <a href="#">Research Toxicology Centre</a>, <a href="#">MPI research</a> (Contract Research Organisations).</p> <p>4# The Drug Commission of the German Pharmacists (Bundesvereinigung Deutscher Apothekerverbände - <a href="#">ABDA</a>) is the Federal Union of German Associations of Pharmacists.</p> <p>5# The two vice-presidents of the German Society of Chemists (Gesellschaft Deutscher Chemiker - GDCh)'s <a href="#">board</a> and the treasurer are employees of the chemical and pharmaceutical industries. Although GDCh's website does not mention it, vice-president <a href="#">Michael Dröscher</a> works for <a href="#">Chemie.NRW</a>, which is part of the Verband der Chemischen Industrie (VCI), the German organisation of the chemical industry.</p> <p>6# No information could be found on the German Society for Experimental and Clinical Pharmacology and Toxicology (Deutsche Gesellschaft für experimentelle und klinische Pharmakologie und Toxikologie - <a href="#">DGPT</a>)'s funding sources. <a href="#">One of the five presidium members</a> is an employee from <a href="#">Sanofi-Aventis</a>, a pharmaceutical company.</p> <p>7# The Association of European Toxicologists and European Societies of Toxicology (<a href="#">EUROTOX</a>) has 5 corporate members: <a href="#">AstraZeneca</a>, <a href="#">Servier</a> (pharmaceutical companies); <a href="#">Solvay</a> (chemical company); <a href="#">Research Toxicology Centre</a>, <a href="#">MPI research</a> (Contract Research Organisations).</p>	<p>3# VIII</p> <p>4# VIII</p> <p>5# VIII</p> <p>6# VIII</p> <p>7# VIII</p>	<p>3# CbC</p> <p>4# CbC</p> <p>5# CbC</p> <p>6# CbC</p> <p>7# CbC</p>	<p>3# no</p> <p>4# no</p> <p>5# yes</p> <p>6# no</p> <p>7# yes</p>	<p>information to assess the interest.</p>	
SILANO Vittorio	<p>1# Chair of the Steering Committee of EU FP7* project Plant Libra (PLANT food supplements: Levels of Intake, Benefit and Risk Assessment). 07/2010 - 07/2011.</p> <p>2# Consultancy for INDENA spa. Related to a preliminary evaluation of the</p>	<p>1# <a href="#">Plant Libra Consortium</a> included private partners such as the <a href="#">European botanical forum</a>, or the European Responsible Nutrition Alliance (<a href="#">ERNA</a>), organisations for the vitamins and food supplements industry.</p> <p>2# <a href="#">INDENA</a> is a pharmaceutical company.</p>	<p>1# III</p> <p>2# V</p>	<p>1# no</p> <p>2# no</p>	<p>1# yes</p> <p>2# yes</p>		<p>1# EU-funded project with private beneficiaries.</p>

	<p>safety of an anti-cancer medicinal product consisting of botanical ingredients. 08/2009 - 04/2010.</p> <p>3# Associate editor of <i>Nutrafoods</i>, a scientific journal. 03/2012 - now.</p>	<p>3# The editor-in-chief of <i>Nutrafoods</i> – an “International Journal on Nutraceuticals, Functional Foods and Novel Foods from Research to Industrial Applications” – is Andrea Poli, scientific director of the Nutrition Foundation of Italy (NFI). The Nutrition Foundation of Italy (NFI) “was created in December 1976 with the goal of enabling interaction and collaboration with government bodies, universities and industry to contribute to the development of scientific research”, says its <a href="#">website</a>. One of its top staff is a former executive of the food company <a href="#">Barilla</a>. NFI is part of an <a href="#">international network of “national nutrition institutes”</a>, most of which are food industry front groups. For example, the Institut français pour la nutrition (French nutrition institute - IFN) is an organisation <a href="#">created</a> by the French confederation of food and drink industries <a href="#">ANIA</a> and the Institut de liaison et d’études des industries de consommation <a href="#">ILEC</a>. It has been recently replaced by the Fonds français pour l’alimentation et la santé (French fund for nutrition and health - FFAS), which is <a href="#">entirely sponsored by the food industry</a>.</p>	3# VIII	3# CbC	3# yes		
	<p>4# Nutrition Foundation of Italy (NFI), a non-profit organisation to contribute to scientific research development, information exchange and promotion of multidisciplinary researches through interaction and collaboration with several governmental and other partners. Member. 01/2005 - now.</p>	<p>4# The Nutrition Foundation of Italy (NFI) “was created in December 1976 with the goal of enabling interaction and collaboration with government bodies, universities and industry to contribute to the development of scientific research”, says its <a href="#">website</a>. One of its top staff is a former executive of the food company <a href="#">Barilla</a>. NFI is part of an <a href="#">international network of “national nutrition institutes”</a>, most of which are food industry front groups. For example, the Institut français pour la nutrition (French nutrition institute - IFN) is an organisation <a href="#">created</a> by the French confederation of food and drink industries <a href="#">ANIA</a> and the Institut de liaison et d’études des industries de consommation <a href="#">ILEC</a>. It has been recently replaced by the Fonds français pour l’alimentation et la santé (French fund for nutrition and health - FFAS), which is <a href="#">entirely sponsored by the food industry</a>.</p>	4# VIII	4# CbC	4# yes		
VAN LOVEREN Henk	<p>1# Teaching and research at Maastricht University. My appointment with Maastricht University is 20% of my time. In the toxicogenomics project, which is about 50% of my time in Maastricht, work is carried out at the account of the Dutch Government (Netherlands</p>		1# IV	1# no	1# ?	1# Insufficient declared information to assess the interest.	

	<p>Genomics Initiative), and in that project, 20% of the budget for the whole project is supplied by a number of companies (chemical, drug, testing). Model compounds are being used for the research but no specific products offered by the participating industries are being tested in the project. In my capacity at Maastricht University, a minority of the funding, i.e. less than 5%, offered in kind, originates from companies. Maastricht University is not performing formal risk assessments other than for scientific reasons. 05/2002 - now.</p> <p>2# Participation as expert/advisor to the ILSI Expert Group on Markers for Immuno-modulation. The immunomodulation expert group is under ILSI Taskforce of Nutrition and immunity. 05/2008 - 07/2012.</p> <p>3# ILSI workshop food health claims. This workshop was organised to discuss approaches for how to evaluate outcomes of studies of food in terms of beneficial effects. The workshop was not intended to any specific products. I took part as an expert taking part in the discussions. There was no outcome of the meeting for which I had to take responsibility. I believe the meeting was held in Montreux. 12/2009.</p>	<p>2# International Life Sciences Institute (ILSI) is an industry-funded organisation.</p> <p>3# International Life Sciences Institute (ILSI) is an industry-funded organisation.</p>	<p>2# V</p> <p>3# IX</p>	<p>2# no</p> <p>3# no</p>	<p>2# yes</p> <p>3# yes</p>	<p>3# Interests belonging to "Consultancy" (V) sector.</p>
VLEMINCKX Christiane						
WESTER Pieter						

**TOTAL CEO = 15 conflicts of interests**  
**= 5 no conflict**  
**/ 20 members**

Diane Benford should not be allowed to chair the CONTAM Panel. Her recent, past consultancies with ILSI (1 and 2#) constitute conflicts of interests according to EFSA rules.

**TOTAL**

Among the 20 experts composing the CONTAM panel, 15 have one or more conflicts of interest and 5 do not have any declared conflict of interest. The total number of interests screened is 73, 45 were determined to constitute a conflict of interest, 13 as not and 15 could not be assessed for lack of declared and publicly available information.

\*FP7 : 7th Framework Programme for Research and Technological Development (European Union research programme)

\*\*FP6 : 6th Framework Programme for Research and Technological Development (European Union research programme)

CbC : Case by case assessment